For how we live.
Screening 2,904 proteins in early pregnancy, researchers found low maternal isthmin-2 was the strongest signal for later preeclampsia or fetal growth restriction, validated in two cohorts.
A Chinese birth cohort of 1,278 pairs found higher prenatal temperatures and heatwaves — especially in the second trimester — tracked with higher creatinine and urea in early childhood.
A transcriptomic sub-study of the CALERIE calorie-restriction trial links 151 genes to preserved leg strength during weight loss, independent of how much body mass was lost.
A trial of an anti-inflammatory antibody cut cardiovascular events without changing lipids. A genetic study of 194,418 people found the inflammation marker everyone measures is not itself causal.
A review in Gut says no intestinal disease can be cured by normalising barrier function, and that it is unproven whether restoring the barrier improves any clinical outcome at all.
A 614-donor autopsy study tied advanced CTE to dementia independently of other brain disease. A separate imaging report in three former athletes hints at a test for the living. The caveats on both are heavy.
The approved tests are for patients already showing cognitive decline. Used on the worried well, a positive result mostly signals a risk that may never become disease — and no treatment follows from it.
A meta-analysis of 45 cohorts found risk rising steadily with every 10 beats per minute. A study of 92,457 wearable users found one person's normal can differ from another's by 70 beats.
In 2023 declining taurine was proposed as a driver of ageing. Two years later the same journal published human, monkey and mouse data in which taurine rose or stayed flat.
Longevity trials want a measurement that moves in months instead of decades. A Berlin study ranked the candidates, and a four-week diet trial showed what a clock does when nothing much happens.
Buntanetap showed dose-dependent cognitive benefit in biomarker-positive patients with mild disease. The company's announcement does not say what happened in the full 351-patient population.
Three February papers push plasma p-tau217 past detection: clock models estimating years to symptom onset, four assays compared head to head, and a real-world audit of what the result changes.
In 85 people with mild cognitive impairment, transient beta-band events recorded at rest differed years before diagnosis. The sample is small and the finding has not been replicated.
The NEJM paper reports 47 children in an open-label trial with no randomised control. The biomarker effect is large; the clinical claim rests on softer ground.
The biomarker effect reported at CTAD is large and sustained over two years. The sample is seven, the design is open dose-escalation, and imaging was available for three.
A small longitudinal study found reduced spindle activity over the temporal lobes in early Alzheimer's — and that lower temporal spindle density tracked with faster decline over up to seven years.
At a Mayo Clinic cohort of 252 patients, 40% of amyloid-negative people tested positive. The manufacturer says it has found a manufacturing problem and put the product on hold.
A decade-on review of chronic traumatic encephalopathy research reports that 5 of 70 veteran donors had features of the pathology and none met the full definition. A small UK rugby study looks elsewhere.
Sequencing hundreds of single neurons from 15 donors with CTE and 4 with repetitive head impacts but no CTE, researchers found the genomic damage tracked the disease, not the exposure.
Seventy-two runners were sampled before and after the 2024 Boston Marathon. Every marker of kidney and intestinal injury rose, and staying hydrated did not change that.
A 13-year-old observational hypothesis finally got its randomised test. In ALASCCA, 160 mg of daily aspirin cut three-year recurrence from 14.1% to 7.7% in biomarker-selected patients.